Heart Repair mRNA Improves Pumping Function in Mice

A modified mRNA treatment encoding Myc and Cyclin T1 improved pumping function in mice after a heart attack, according to a University of Cambridge story and a paper in Nature Cardiovascular Research, both dated 9 November 2026. The work, by Aleksandra Boikova and colleagues at Cambridge, QIMR Berghofer and AstraZeneca, and funded by the British Heart Foundation, is a mouse study only. It is not a treatment for patients.

Cambridge says the heart repair mRNA produced a stronger heartbeat and increased the amount of blood pumped with each beat “by around 10%,” compared with mice that received a mock treatment. The paper reports the change in left-ventricular ejection fraction at 28 days as −37±3% in control animals and −26±3% in treated animals, and at 12 weeks as −16.1% versus −7.1%. The benefit was still present at 12 weeks, and the authors report no adverse effects observed in the mice, including no tumours in the organs they examined at that point.

The delivery method is a hard stop for any jump to the clinic. The paper says the team used a lipofectamine reagent to administer the modified RNA in the mice, “however, this method of delivery could not be used in patients.” Larger-animal studies, and then human trials, would be needed before any clinical use could be considered.

A short pulse of two proteins, in mice

Adult heart muscle cells do not normally divide to replace tissue lost after a heart attack. The researchers designed a modified mRNA that briefly instructs cells to make Myc and Cyclin T1, two proteins involved in cell-cycle activity, and injected it into the heart muscle of mice at the time of an experimental infarct. The paper describes a short, local pulse of protein expression: Myc and Cyclin T1 were detected at one and four hours after injection and were not observed in heart tissue at 24 hours.

That transience is part of the design. The authors argue that a short pulse is safer than sustained expression, after a related genetic model with broader activation caused severe illness in mice. In the mRNA experiments, treated mice showed more signs of heart-muscle cell division than controls, and more left-ventricular muscle area at 28 days. Cambridge says the treatment is short-lived and localised, and is not expected to cause any permanent modification to the heart cells.

Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation, said the work “shows clear potential for heart patients,” while stressing that “the research is in mice, and still at an early stage.” Dr Catherine Wilson, co-senior author at Cambridge’s Department of Pharmacology and the Gurdon Institute, said the approach “could help the heart to repair itself,” rather than only treating symptoms. Those are researchers’ hopes for a future therapy, not a result already shown in people.

The UK interest is obvious and still prospective. Cambridge notes that around 200,000 people in the UK are diagnosed with heart failure each year, and that existing treatments can reduce symptoms and slow progression but cannot regenerate muscle that has already been lost. Nothing in this paper changes that clinical picture today.

Why a mouse result is not a patient result

A 10% improvement in pumping, or an 11-point narrower fall in ejection fraction at 28 days, is a meaningful laboratory signal. It is also a result in mice, measured after an experimental heart attack and an open-chest injection. The paper’s own 12-week figures still describe treated animals as having weaker function than they did before the injury, just less weak than the controls. That is repair relative to a mock treatment, not a restoration of a healthy heart.

The delivery caveat is not a footnote. Lipofectamine is a laboratory transfection reagent. The authors say plainly that this method could not be used in patients, and that a future path would need a different formulation, such as targeted lipid nanoparticles, and a less invasive way of getting the RNA into the heart. Until those exist and are tested in larger animals, the mRNA construct remains a prototypical research tool.

TSN has covered other early biomedical results that improved outcomes in mice, including a Cambridge animal-study vaccine against bird flu and a protein that boosted CAR-T cells against colorectal tumours in mice. In each case the useful question is the same: what has been shown in the animal, and what has not been shown in patients. A separate UK imaging study, in which AI heart MRI readings predicted survival slightly better than experts, is about measuring damage, not reversing it.

The next evidence that would change the story is not another press summary of the mouse data. It is a larger-animal study with a delivery method that could actually be used in people, and a clear safety read on rhythm and off-target effects. Until then, this remains a carefully measured result in mice.